A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Acadia Pharmaceuticals Inc stock. As of the latest transaction made, Two Sigma Advisers, LP holds 55,400 shares of ACAD stock, worth $819,366. This represents 0.0% of its overall portfolio holdings.

Number of Shares
55,400
Previous 22,000 151.82%
Holding current value
$819,366
Previous $406,000 121.67%
% of portfolio
0.0%
Previous 0.0%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$14.62 - $18.42 $488,308 - $615,228
33,400 Added 151.82%
55,400 $900,000
Q1 2024

May 15, 2024

SELL
$17.79 - $30.86 $846,804 - $1.47 Million
-47,600 Reduced 68.39%
22,000 $406,000
Q4 2023

Feb 14, 2024

BUY
$20.78 - $31.77 $1.06 Million - $1.62 Million
50,900 Added 272.19%
69,600 $2.18 Million
Q3 2023

Nov 14, 2023

SELL
$20.84 - $33.47 $3.16 Million - $5.08 Million
-151,700 Reduced 89.03%
18,700 $389,000
Q2 2023

Aug 14, 2023

BUY
$17.8 - $25.65 $2.81 Million - $4.06 Million
158,100 Added 1285.37%
170,400 $4.08 Million
Q1 2023

May 15, 2023

BUY
$16.32 - $20.92 $200,736 - $257,316
12,300 New
12,300 $231,000
Q2 2022

Aug 15, 2022

SELL
$13.01 - $27.22 $524,303 - $1.1 Million
-40,300 Reduced 70.83%
16,600 $234,000
Q1 2022

May 16, 2022

BUY
$20.94 - $27.5 $1.19 Million - $1.56 Million
56,900 New
56,900 $1.38 Million
Q2 2021

Aug 16, 2021

SELL
$19.4 - $27.42 $3.68 Million - $5.2 Million
-189,500 Closed
0 $0
Q1 2021

May 17, 2021

SELL
$25.02 - $54.99 $5.83 Million - $12.8 Million
-233,100 Reduced 55.16%
189,500 $4.89 Million
Q4 2020

Feb 16, 2021

SELL
$41.04 - $56.79 $8.85 Million - $12.2 Million
-215,600 Reduced 33.78%
422,600 $22.6 Million
Q3 2020

Nov 16, 2020

BUY
$36.42 - $57.0 $8.67 Million - $13.6 Million
238,100 Added 59.51%
638,200 $26.3 Million
Q2 2020

Aug 14, 2020

BUY
$39.26 - $52.73 $13.3 Million - $17.8 Million
338,400 Added 548.46%
400,100 $19.4 Million
Q1 2020

May 15, 2020

SELL
$31.65 - $46.87 $1.36 Million - $2.02 Million
-43,100 Reduced 41.13%
61,700 $2.61 Million
Q4 2019

Feb 14, 2020

SELL
$36.21 - $51.4 $90,525 - $128,500
-2,500 Reduced 2.33%
104,800 $4.48 Million
Q3 2019

Nov 14, 2019

BUY
$22.22 - $44.01 $799,920 - $1.58 Million
36,000 Added 50.49%
107,300 $3.86 Million
Q2 2019

Aug 14, 2019

SELL
$23.32 - $28.12 $41,976 - $50,616
-1,800 Reduced 2.46%
71,300 $1.91 Million
Q1 2019

May 15, 2019

BUY
$16.17 - $27.38 $300,762 - $509,268
18,600 Added 34.13%
73,100 $1.96 Million
Q4 2018

Feb 14, 2019

BUY
$14.32 - $22.92 $780,440 - $1.25 Million
54,500 New
54,500 $881,000

Others Institutions Holding ACAD

About ACADIA PHARMACEUTICALS INC


  • Ticker ACAD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 161,843,008
  • Market Cap $2.39B
  • Description
  • ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's p...
More about ACAD
Track David A. Siegel's Portfolio

Track David A. Siegel Portfolio

Follow David A. Siegel (Two Sigma Advisers, LP) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.